In HCC, multi-kinase inhibitors (MKIs) such as Sorafenib, Lenvatinib, Regorafenib, and Cabozantinib target various receptor tyrosine kinases to disrupt crucial signaling pathways involved in tumor growth and angiogenesis (Llovet et al., 2008; Xiang et al., 2014; Kudo et al., 2018; Zhang et al., 2021). This evidence concerns the gene NTRK1 and neoplasm.